Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explored the roles of β-catenin and sclerostin levels in patients with androgenic and alopecia areata, analyzing their potential involvement in the hair follicle morphogenesis and Wnt signaling pathway.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

This study found that a topical hedgehog agonist can stimulate hair growth by promoting the transition from the resting to growth phase of the hair cycle in adult mouse skin.

This article explores the potential of formyl-peptide receptor 2 agonists as innovative anti-inflammatory drugs, highlighting their ability to mimic the body's natural inflammation response, but it presents no new clinical findings.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.

This study found that DKK1 and WNT10b are paracrine factors that modulate hair follicle stem cell differentiation inhibition, contributing to androgenetic alopecia by affecting Wnt signaling in androgen-sensitive dermal papilla cells after dihydrotestosterone stimulation.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.

This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.

This study suggests that while PTH rP initially seemed to shorten the hair cycle by transitioning hair follicles from anagen to catagen, more relevant models indicate it ultimately accelerates and stimulates hair growth.

The researchers reported that Gambogic Amide may prevent hair greying and promote hair growth by maintaining follicle pigmentation in vitro through activation and migration of melanocytes.

This study found that pimozide, d-butaclamol, and pituitary pars intermedia grafts darken hair color in agouti C3H Avy mice, suggesting dopaminergic inhibition influences peptide-controlled hair color cycling.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study highlights the potential of GPR30 and its selective agonists as promising therapeutic targets for treating hair loss disorders and conditions that respond to estrogen, emphasizing their role in modulating hair growth.

In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.

This study found that GPR40 agonists may promote hair growth by inducing angiogenesis via specific molecular pathways in both cell and animal models, suggesting potential for hair loss treatment.

This study found that dihydrotestosterone alters the balance of Wnt pathway regulators in dermal papilla cells, hindering hair follicle stem cell differentiation and contributing to hair follicle miniaturization.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that both a high dose of CPA and GnRHa are effective for treating hirsutism in hyperandrogenic women, but GnRHa with add-back therapy may lead to a longer remission period.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.